Last edition
News about "ophthalmic diseases"
European Commission approves EYLUXVI (ALT-L9) by Alteogen
EYLUXVI is the second biosimilar approved by the European Commission for Alteogen, following the launch of the Herceptin biosimilar in China through its partner Qilu Pharmaceutical.
Ophthalmic Diseases | 18/09/2025 | By Dineshwori
Nona Biosciences, Kodiak Sciences to Power Next-Gen Antibody Therapies for Ophthalmic Diseases
The Harbour Mice platform generates fully human monoclonal antibodies in both the two heavy and two light chains (H2L2) format and the heavy chain-only (HCAb) format, eliminating the need for additional engineering or humanization.
Ophthalmic Diseases | 11/12/2024 | By Aishwarya | 209
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy